VOLUME 21 , ISSUE 2 ( 2017 ) > List of Articles
Ankita Sood, Vidya Nagar, Rudrarpan Chaterjee, Aniruddha Kaushik, Sameer Vyahalkar
Keywords : Atypical hemolytic uremic syndrome, complement system, eculizumab, plasma exchange, thrombotic microangiopathy
Citation Information : Sood A, Nagar V, Chaterjee R, Kaushik A, Vyahalkar S. Complements spurned: Our experience with atypical hemolytic uremic syndrome. Indian J Crit Care Med 2017; 21 (2):102-104.
DOI: 10.4103/ijccm.IJCCM_341_16
License: CC BY-ND 3.0
Published Online: 01-02-2017
Copyright Statement: Copyright © 2017; The Author(s).
Atypical hemolytic uremic syndrome (aHUS) is a rare disorder resulting from a dysregulated activation of the alternative pathway of the complement system. It results in significant morbidity and mortality if not diagnosed and treated promptly. It lends itself to myriad renal and extrarenal manifestations, all potentially disabling. Eculizumab, a monoclonal antibody to complement C5 is now the widely accepted norm for treatment. However, in resource-limited settings, plasma exchange if instituted early may be as beneficial. We report a case of aHUS treated with extended plasma exchange with excellent results. Critical care monitoring is essential for the management of the disease in view of a tendency to develop multiple complications. Long-term immunosuppression may be successful in maintaining remission.
© Jaypee Brothers Medical Publishers (P) LTD.
We use cookies on this site to enhance your user experience.
By clicking any link on this page you are giving your consent for us to set cookies.